Investigational drug · Phase 2
ODM-212
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumours, Mesothelioma, Pancreatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ODM-212"
First trial start
2023
Oct 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ODM-212", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumours
- Mesothelioma
- Pancreatic Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ODM-212" as an intervention, largest first.
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid TumoursRecruiting
Orion Corporation, Orion PharmaIndustry
NCT06725758 · 315 participants (planned) · Start Oct 26, 2023 · Primary completion Dec 31, 2027
Drug: ODM-212 · For: Solid Tumours
Sites: Los Angeles, California; Orange, California; St Louis, Missouri · 20 sites in all
Orion Corporation, Orion PharmaIndustry
NCT07563738 · 229 participants (planned) · Start Mar 27, 2026 · Primary completion Sep 2029
Drug: ODM-212; Ipilimumab and nivolumab and 2 more · For: Mesothelioma; Pancreatic Cancer; NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Los Angeles, California; Orange, California; Fort Worth, Texas · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumours
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
- AZD4956Phase 21 trial
AstraZeneca · Solid Tumours
- BMS-986517Phase 21 trial
Bristol Myers Squibb · Solid Tumours
- EP0089-101Phase 21 trial
Ellipses Pharma · Solid Cancers, Solid Tumours
- GSK5864399Phase 21 trial
GSK · Solid Tumours
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.